(2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid | 203321-56-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid
• 英文别名: 2-(3,3-difluorocyclopentyl)-2-hydroxy-2-phenylacetic acid；(2R)-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid；(2R)-2-((1R)-3,3-difluorocyclopentyl)-2-hydroxy-2-phenylacetic Acid
• CAS: 203321-56-6
• 化学式: C₁₃H₁₄F₂O₃
• 分子量: 256.249
• InChiKey: GPUGYUSBIRXKND-MFKMUULPSA-N

物化性质

• 沸点：
  397.9±27.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid 在 20percent Pd(OH)2 氢气 、 三乙酰氧基硼氢化钠 、 1-羟基苯并三唑 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 氯仿 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 40.0h， 生成 (2R)-N-[1-(thien-3-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide
  参考文献：
  名称：

  A Potent, Long-Acting, Orally Active (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide:  A Novel Muscarinic M₃ Receptor Antagonist with High Selectivity for M₃ over M₂ Receptors

  摘要：

  A novel series of (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamides was designed and synthesized based on the structure and biological profiles of an active metabolite 2 of our prototype muscarinic M-3 receptor selective antagonist 1, to develop a potent, long-acting, orally active M-3 antagonist for the treatment of urinary tract disorders, irritable bowel syndrome, and respiratory disorders. Investigation of (2R)-2-[(IR)-3,3-difluorocyclopentyl] -2-hydroxy-2-phenylacetamides containing a phenyl or heterocyclic ring as the piperidinyl side chain in place of the 4-methyl-3-pentenyl moiety of 15a revealed that this acid moiety was a versatile template for improving the selectivity for M-3 over M-2 receptors in comparison With the corresponding cyclopentylphenylacetic acid group: However, since the in vitro metabolic stability of these analogues was insufficient compared with that of 2, further derivatization was performed by introducing an appropriate hydrophilic group into the phenyl or 2-pyridyl ring. Thus, the 1;(6-aminopyridin-2-ylmethyl)piperidine analogue 15y exhibiting 190-fold selectivity for M-3 receptors (K-i = 2.8 nM) over M-2 receptors (K-i = 530 nM) in a human binding assay and-good in vitro metabolic stability in dog and human hepatic microsomes:was identified; This compound has excellent oral activity at 4 h after oral dosing (1 mg/kg), inhibiting methacholine-induced : bronchoconstriction in dogs, and may be useful in clinical situations in which M-3 over M-2 selectivity is desirable.

  DOI：

  10.1021/jm0003135
• 作为产物：
  描述：

  D-扁桃酸 在 N,N,4-三甲基哌嗪-1-乙胺 、 lithium hydroxide 、 对甲苯磺酸 、 [双(2-甲氧基乙基)胺]三氟化硫 、 lithium diisopropyl amide 作用下， 以 甲醇 、 乙二醇二甲醚 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 49.5h， 生成 (2R)-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetic acid
  参考文献：
  名称：

  通过非对映选择性迈克尔反应，选择性脱氧氟化和芳香族金属-卤素交换反应合成毒蕈碱受体拮抗剂。

  摘要：

  描述了一种结构独特的新型M（3）拮抗剂1的有效合成。化合物1可以方便地在酰胺键上逆合成合成，以揭示酸部分2和胺片段3。关键中间体2的合成通过ZnCl（2）-MAEP配合物19催化的二氧戊环7与2-的非对映选择性Michael反应突出显示。环戊烯-1-一（5）建立连续的四级-三级手性中心，然后在催化性BF（3）.OEt（2）的存在下，使用Deoxofluor建立酮17的二元双氟化。胺部分3的合成突出了一种新型的n-Bu（3）MgLi镁-卤素交换反应，用于2,6-二溴吡啶的选择性官能化。这种新的实用的金属化方案消除了低温条件，并用DMF淬灭后，以极好的收率得到6-溴-2-甲酰基吡啶（26）。进一步的转化通过35的还原胺化，Pd催化的芳族胺化和脱保护得到胺片段3。最后，通过两个片段的偶联完成了1的高度收敛合成。该合成已用于制备多千克量的原料药。

  DOI：

  10.1021/jo0157425

文献信息

• N-acyl cyclic amine derivatives
  申请人：Banyu Pharmaceutical Co Ltd

  公开号：US06140333A1

  公开（公告）日：2000-10-31

  The invention relates to compounds represented by the general formula [I] ##STR1## [wherein Ar means an aryl group or a heteroaryl group which may have a substitutive group selected from a group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group; R.sup.1 means a C.sub.3 -C.sub.6 cycloalkyl group which is substitutable with a fluorine atom; R.sup.2 and R.sup.4 mean hydrogen atoms, groups represented by --(A.sup.1).sub.m --NH--B or the like; R.sup.3 and R.sup.5 mean hydrogen atoms, C.sub.1 -C.sub.6 aliphatic hydrocarbon groups or the like which are substitutable with a lower alkyl group(s); n means 0 or 1; and X means an oxygen atom or a sulfur atom]. Compounds according to the invention, since they not only have potent selective antagonistic activity against muscarinic M.sub.3 receptors but also exhibit excellent oral activity, durability of action and pharmacokinetics, are very useful as safe and effective remedies against respiratory, urinary and digestive diseases with little adverse side effects.

  该发明涉及由通式[I]表示的化合物 ##STR1## [其中Ar表示芳基或杂环基，可能具有从卤原子、较低烷基基团和较低烷氧基团中选择的取代基; R.sup.1表示可用氟原子取代的C.sub.3-C.sub.6环烷基基团; R.sup.2和R.sup.4表示氢原子，表示为--(A.sup.1).sub.m--NH--B或类似基团; R.sup.3和R.sup.5表示氢原子，可用较低烷基基团取代的C.sub.1-C.sub.6脂肪烃基团或类似基团; n表示0或1; X表示氧原子或硫原子]。根据该发明的化合物，由于它们不仅具有对M.sub.3胆碱能受体具有强效选择性拮抗活性，而且表现出优异的口服活性、持久作用和药代动力学特性，因此在对抗呼吸、泌尿和消化系统疾病时非常有用，且副作用很小，是安全有效的药物。
• Ester derivatives
  申请人：——

  公开号：US20030191316A1

  公开（公告）日：2003-10-09

  This invention relates to compounds which exhibit selective muscarinic M 3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); 1 [in which A signifies a group expressed by a formula (a 0 ) or (b 0 ); 2 Ar signifies optionally substituted aryl or heteroaryl; B 1 and B 2 signify aliphatic hydrocarbon; R 1 signifies fluorine-substituted cycloalkyl; R 2 , R 3 and R 4 signify lower alkyl, single bond or alkylene bonded to B 1 , or R 2 and R 3 are united to signify alkylene; R 5 and R 7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B 2 ; R 6 signifies hydrogen, lower alkyl or a group expressed as —N(R 8 )R 9 ; and X − signifies an anion].

  这项发明涉及表现出选择性肌肉M3受体拮抗作用、副作用小、适用于吸入疗法并且可用作治疗呼吸系统疾病的治疗剂的化合物，其一般式为（I）； 其中A表示由式（a0）或（b0）表示的基团； Ar表示可选择取代的芳基或杂环芳基；B1和B2表示脂肪烃基；R1表示氟取代的环烷基；R2、R3和R4表示较低的烷基、与B1结合的单键或烷基，或者R2和R3结合表示烷基；R5和R7表示氢、较低的烷基，或者与B2结合的单键或烷基；R6表示氢、较低的烷基或表示为—N(R8)R9的基团；X-表示阴离子。
• Fluorine-containing 1,4-disubstituted piperidine derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05948792A1

  公开（公告）日：1999-09-07

  Novel fluorine-containing 1,4-disubstituted piperidine derivatives, represented by general formula \x9bI! ##STR1## such as, for example, (2R)-N-\x9b1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl!-2-\x9b(1R)-3,3-difluoroc yclopentyl!-2-hydroxy-2-phenylacetamide or pharmaceutically acceptable salt thereof, are potent and selective antagonists for muscarinic M.sub.3 receptors with little side effects. The compounds of formula \x9bI! exhibit excellent oral activity, duration of activity and pharmacolkinetics. They are useful for treatment and prophylaxis of respiratory diseases, such as chronic obstructive pulmonary diseases; urinary diseases, such as urinary incontinence; and digestive diseases, such as irritable bowel syndrome, and motion sickness.

  含氟的新型1,4-二取代哌啶衍生物，通式\x9bI! ##STR1##例如，(2R)-N-\x9b1-(6-氨基吡啶-2-基甲基)哌啶-4-基!-2-\x9b(1R)-3,3-二氟环戊基!-2-羟基-2-苯乙酰胺或其药用盐，是对M.sub.3受体具有强效和选择性拮抗作用的化合物，副作用很小。通式\x9bI!的化合物表现出优异的口服活性、活性持续时间和药代动力学。它们可用于治疗和预防呼吸系统疾病，如慢性阻塞性肺疾病；泌尿系统疾病，如尿失禁；以及消化系统疾病，如肠易激综合征和晕动病。
• Muscarinic M3 receptor antagonists with (2R)-2-[(1R)-3,3-Difluorocyclopentyl]-2-hydroxyphenylacetamide Structures. Part 2
  作者：Yoshio Ogino、Norikazu Ohtake、Kensuke Kobayashi、Toshifumi Kimura、Toru Fujikawa、Takuro Hasegawa、Kazuhito Noguchi、Toshiaki Mase

  DOI：10.1016/s0960-894x(03)00350-0

  日期：2003.7

  led to a 4-aminopiperidinamide (2l) with a K(i) value of 5.1 nM and with a selectivity of the M(3) receptor that was 46-fold greater than that of the M(2) receptor. Further derivatization of 2l by inserting a spacer group or by incorporating alkyl group(s) into the amine part resulted in the identification of an 4-(aminoethyl)piperidinamide 2l-b with a K(i) value of 3.7 nM for the M(3) receptor and a

  进行了我们原始毒蕈碱型M（3）受体拮抗剂1的胺部分的优化，以鉴定出优于1的M（3）受体拮抗剂。对氮原子上带有疏水取代基的各种二胺部分的化合物进行了筛选。 M（3）受体的结合亲和力和M（3）超过M（1）和M（2）受体的选择性。该过程导致了4-氨基哌啶酰胺（2l），其K（i）值为5.1 nM，M（3）受体的选择性比M（2）受体大46倍。通过插入间隔基或将烷基引入胺部分进一步2l衍生化，从而鉴定出K（i）值为3的4-（氨基乙基）哌啶酰胺2l-b。
• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：Kumar Naresh

  公开号：US20100056496A1

  公开（公告）日：2010-03-04

  The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors. Formula (I) or a pharmaceutically accepted salt, pharmaceutically acceptable solvate, enantiomers, diastereomer, polymorph or N-oxide thereof, wherein X is.

  本发明通常涉及抗胆碱受体拮抗剂，这些拮抗剂可用于治疗经由胆碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病，此外，本发明还涉及制备所述化合物的过程、其制药组合物以及治疗经由胆碱受体介导的疾病的方法。其中，公式（I）或其药学上可接受的盐、药学上可接受的溶剂化物、对映体、非对映异构体、多晶形或N-氧化物，其中X为。